Dr. Daniel S. Mishkin, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Mcgill University, Faculty of Medicine (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 307
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: Mcgill University, Faculty of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
MA license 220601
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Beth Israel Deaconess Hospital - Milton Milton, MA
Medical groups
- Atrius Health Inc (1,222 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 307
- Services billed
- 721
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Biopsy of large bowel using a flexible endoscope | 157 | 156 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 120 | 119 |
| Established patient office or other outpatient visit, 40-54 minutes | 100 | 63 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 80 | 72 |
| Insertion of needle into vein for collection of blood sample | 34 | 30 |
| Established patient office or other outpatient visit, 30-39 minutes | 32 | 28 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 22 | 19 |
| Blood test, comprehensive group of blood chemicals | 20 | 17 |
| Imaging of digestive tract done from the inside of the digestive tract | 17 | 17 |
| New patient office or other outpatient visit, 45-59 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Omeprazole Other prescribers in Weymouth, MA | 165 |
| Gavilyte-C (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Weymouth, MA | 93 |
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in Weymouth, MA | 91 |
| Peg3350-Sod Sul-Nacl-Kcl-Asb-C (peg3350/sod sul/nacl/kcl/asb/c) | 72 |
| Pantoprazole Sodium Other prescribers in Weymouth, MA | 46 |
| Famotidine Other prescribers in Weymouth, MA | 33 |
| Linzess (linaclotide) Other prescribers in Weymouth, MA | 32 |
| Mesalamine Other prescribers in Weymouth, MA | 30 |
| Amitriptyline Hcl Other prescribers in Weymouth, MA | 24 |
| Colestipol Hcl Other prescribers in Weymouth, MA | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $500 in total to this clinician.
| Sanofi US Services Inc. | $500 |
|---|
| Consulting Fee | $500 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sanofi US Services Inc. Jun 19, 2025 | Consulting Fee DUPIXENT · Immunology | $500 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $4,950 in research payments for these studies, mostly to the institutions running them.
- Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
AbbVie Inc. · Terminated · NCT05785715 - A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepati…
Boehringer Ingelheim International GmbH - A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))
Sanofi US Services Inc. · Active, not recruiting · NCT05731128
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.